Tumor Suppressive Role of MiR-569 in Lung Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Mar 16

PMID 29541173

Citations 6

Authors

Yi Ping Zheng

Linxia Wu

Jie Gao

Yanfu Wang

Affiliations

Soon will be listed here.

Abstract

microRNAs (miRs) are targets for genomic aberrations and emerging treatments against cancer. It has been demonstrated that targeting miR-569 may potentially benefit patients with ovarian or breast cancer. However, the exact roles of miR-569 remain unclear in human lung cancer cells. Using the reverse transcription-quantitative polymerase chain reaction (RT-qPCR), it was demonstrated that miR-569 expression was consistently decreased in lung cancer cells. As well as cell proliferation and migration inhibition, apoptosis and cell arrest at the G1 phase were induced following reversion of miR-569 expression in lung cancer cells. The present study demonstrated that miR-569 was able to downregulate FOS and high mobility group A2 mRNA and protein expression using RT-qPCR and western blot analysis. The observed role of miRNA-569 in lung cancer cells in the present study suggested that it may be a novel and promising therapeutic target, and a novel biomarker for detecting lung cancer.

Citing Articles

Topology and Dynamics of Transcriptome (Dys)Regulation.

Planat M, Chester D Int J Mol Sci. 2024; 25(9).

PMID: 38732192 PMC: 11084388. DOI: 10.3390/ijms25094971.

Systematic Investigation of the Diagnostic and Prognostic Impact of LINC01087 in Human Cancers.

De Palma F, Carbonnier V, Salvatore F, Kroemer G, Pol J, Maiuri M Cancers (Basel). 2022; 14(23).

PMID: 36497462 PMC: 9738797. DOI: 10.3390/cancers14235980.

Circular RNA hsa_circ_0051040 Promotes Hepatocellular Carcinoma Progression by Sponging miR-569 and Regulating ITGAV Expression.

Ju L, Yao M, Lu R, Cao Y, Wang H, Yuan L Cells. 2022; 11(22).

PMID: 36429000 PMC: 9688127. DOI: 10.3390/cells11223571.

microRNA-569 inhibits tumor metastasis in pancreatic cancer by directly targeting NUSAP1.

Guo X, Li Y, Che X, Hou K, Qu X, Li C Aging (Albany NY). 2022; 14(8):3652-3665.

PMID: 35483343 PMC: 9085231. DOI: 10.18632/aging.204035.

The Assessment of Selected miRNA Profile in Familial Mediterranean Fever.

Kahraman C, Egin M, Tatar A, Turkez H, Mardinoglu A Biomed Res Int. 2021; 2021:6495700.

PMID: 34692839 PMC: 8528586. DOI: 10.1155/2021/6495700.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Go H, Jeon Y, Park H, Sung S, Seo J, Chung D . High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol. 2010; 5(3):305-13. DOI: 10.1097/JTO.0b013e3181ce3d1d. View

Di Cello F, Hillion J, Hristov A, Wood L, Mukherjee M, Schuldenfrei A . HMGA2 participates in transformation in human lung cancer. Mol Cancer Res. 2008; 6(5):743-50. PMC: 3086547. DOI: 10.1158/1541-7786.MCR-07-0095. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Bray F, Jemal A, Grey N, Ferlay J, Forman D . Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012; 13(8):790-801. DOI: 10.1016/S1470-2045(12)70211-5. View

Farazi T, Spitzer J, Morozov P, Tuschl T . miRNAs in human cancer. J Pathol. 2010; 223(2):102-15. PMC: 3069496. DOI: 10.1002/path.2806. View

Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T . HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog. 2007; 46(7):503-11. DOI: 10.1002/mc.20235. View

Yang Y, Zhang P, Zhao Y, Yang J, Jiang G, Fan J . Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer. Cancer Biol Ther. 2015; 17(5):515-25. PMC: 4910912. DOI: 10.1080/15384047.2015.1095405. View

Li F, Liu J, Li S . MicorRNA 106b ∼ 25 cluster and gastric cancer. Surg Oncol. 2013; 22(2):e7-10. DOI: 10.1016/j.suronc.2013.01.003. View

10.

van de Vrie M, Heymans S, Schroen B . MicroRNA involvement in immune activation during heart failure. Cardiovasc Drugs Ther. 2011; 25(2):161-70. PMC: 3094524. DOI: 10.1007/s10557-011-6291-y. View

11.

Grose D, Morrison D, Devereux G, Jones R, Sharma D, Selby C . The impact of comorbidity upon determinants of outcome in patients with lung cancer. Lung Cancer. 2014; 87(2):186-92. DOI: 10.1016/j.lungcan.2014.11.012. View

12.

Wu Y, Song Y, Liu H . [Expression and its clinical significance of HMGA2 in the patients with non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi. 2010; 11(3):377-81. DOI: 10.3779/j.issn.1009-3419.2008.03.005. View

13.

Wu J, Wei J . HMGA2 and high-grade serous ovarian carcinoma. J Mol Med (Berl). 2013; 91(10):1155-65. DOI: 10.1007/s00109-013-1055-8. View

14.

Mehta A, Dobersch S, Romero-Olmedo A, Barreto G . Epigenetics in lung cancer diagnosis and therapy. Cancer Metastasis Rev. 2015; 34(2):229-41. DOI: 10.1007/s10555-015-9563-3. View

15.

Joshi P, Middleton J, Jeon Y, Garofalo M . MicroRNAs in lung cancer. World J Methodol. 2014; 4(2):59-72. PMC: 4202482. DOI: 10.5662/wjm.v4.i2.59. View

16.

Park S, Shell S, Radjabi A, Schickel R, Feig C, Boyerinas B . Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007; 6(21):2585-90. DOI: 10.4161/cc.6.21.4845. View

17.

Esquela-Kerscher A, Slack F . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69. DOI: 10.1038/nrc1840. View

18.

Gartel A, Kandel E . miRNAs: Little known mediators of oncogenesis. Semin Cancer Biol. 2008; 18(2):103-10. DOI: 10.1016/j.semcancer.2008.01.008. View

19.

Xiang Q, Tang H, Yu J, Yin J, Yang X, Lei X . MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2. Pharmazie. 2013; 68(4):274-81. View

20.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View